Menarini Bags J&J's Cellsearch To Strengthen Liquid Biopsy Offering

Johnson & Johnson's Janssen Diagnostics has sold its Cellsearch business, the first and only US FDA-approved circulating tumor cell capture system associated with liquid biopsies, to Italy's Menarini. The latter intends to combine the system with its own DEPArray technology, taking Cellsearch beyond CTC enumeration and into analysis.

More from In Vitro Diagnostics

More from Diagnostics